ERAP2 and familial pancreatic carcinoma: Compared with gemcitabine alone, knockdown ERAP2 combined with gemcitabine further reduced the migration ability of pancreatic cancer cells, and the invasion ability was more significantly inhibited (Figure 7C, 7D).